MY198240A - Compositions and methods related to scavanger particles priority claim - Google Patents
Compositions and methods related to scavanger particles priority claimInfo
- Publication number
- MY198240A MY198240A MYPI2017001935A MYPI2017001935A MY198240A MY 198240 A MY198240 A MY 198240A MY PI2017001935 A MYPI2017001935 A MY PI2017001935A MY PI2017001935 A MYPI2017001935 A MY PI2017001935A MY 198240 A MY198240 A MY 198240A
- Authority
- MY
- Malaysia
- Prior art keywords
- compositions
- scavanger
- priority
- particles
- methods related
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 239000002245 particle Substances 0.000 title 1
- 244000052769 pathogen Species 0.000 abstract 2
- 230000001717 pathogenic effect Effects 0.000 abstract 2
- 230000004071 biological effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
- A61K47/6937—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol the polymer being PLGA, PLA or polyglycolic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5115—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nanotechnology (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Ceramic Engineering (AREA)
- Dermatology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Optics & Photonics (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Psychiatry (AREA)
Abstract
The disclosure provides, among other things, compositions that bind to and inhibit the biological activity of soluble biomolecules, as well as pharmaceutical compositions thereof. The compositions may comprise a plurality of paiiicles that specifically bind a target, such as a soluble biomolecule or a biomolecule on the surface of a pathogen, to inhibit the target ( or pathogen) from interacting with other molecules or cells. Also provided herein are a number of applications ( e.g., therapeutic applications) in which the compositions are useful. (Fig. 1)
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562186838P | 2015-06-30 | 2015-06-30 | |
US201562198519P | 2015-07-29 | 2015-07-29 | |
US201562198541P | 2015-07-29 | 2015-07-29 | |
US201562236507P | 2015-10-02 | 2015-10-02 | |
US201662319092P | 2016-04-06 | 2016-04-06 | |
PCT/US2016/040022 WO2017004159A1 (en) | 2015-06-30 | 2016-06-29 | Compositions and methods related to scavanger particles |
Publications (1)
Publication Number | Publication Date |
---|---|
MY198240A true MY198240A (en) | 2023-08-16 |
Family
ID=57609422
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MYPI2017001935A MY198240A (en) | 2015-06-30 | 2016-06-29 | Compositions and methods related to scavanger particles priority claim |
Country Status (14)
Country | Link |
---|---|
US (1) | US20180256747A1 (en) |
EP (1) | EP3316864A4 (en) |
JP (3) | JP7370691B2 (en) |
KR (1) | KR20180043785A (en) |
CN (4) | CN114129737A (en) |
AU (2) | AU2016285868B2 (en) |
CA (1) | CA2991142A1 (en) |
EA (1) | EA201890170A1 (en) |
HK (1) | HK1255328A1 (en) |
IL (2) | IL256445B2 (en) |
MX (3) | MX2017017051A (en) |
MY (1) | MY198240A (en) |
SG (1) | SG10201913518XA (en) |
WO (1) | WO2017004159A1 (en) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA035898B1 (en) | 2014-10-03 | 2020-08-28 | НАНОТИКС, ЭлЭлСи | Compositions and methods for inhibiting the biological activity of soluble biomolecules |
KR20180034619A (en) | 2015-07-29 | 2018-04-04 | 나노틱스 엘엘씨 | Module compositions for eradicating soluble biomolecules and related methods |
EP3411022B1 (en) * | 2016-02-01 | 2021-09-15 | Emory University | Particles for targeted delivery and uses in managing bleeding or blood clotting |
US10858422B2 (en) | 2016-05-31 | 2020-12-08 | Abcentra, Llc | Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody |
WO2017210360A1 (en) | 2016-05-31 | 2017-12-07 | Cardiovax, Llc | Methods for diagnosing and treating systemic lupus erythematosus |
WO2018129207A1 (en) * | 2017-01-04 | 2018-07-12 | Nanotics, Llc | Methods for assembling scavenging particles |
AU2018234810B2 (en) | 2017-03-15 | 2023-05-11 | Pandion Operations, Inc. | Targeted immunotolerance |
WO2018217989A1 (en) | 2017-05-24 | 2018-11-29 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
CN108404118A (en) * | 2017-06-14 | 2018-08-17 | 张建宁 | The new application of people source lactadherin subtype protein |
EP3477305A1 (en) | 2017-10-25 | 2019-05-01 | Universität Heidelberg | Delta-like ligand 1 for diagnosing severe infections |
US10174092B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
FR3094268B1 (en) * | 2019-03-28 | 2021-03-19 | Carbiolice | MULTI-LAYER ENZYMED ARTICLE |
EP3894857B1 (en) | 2019-04-15 | 2022-09-07 | Nanologica AB | Empty porous particles for use in treatment, prevention and/or postponement of degeneration of neurodegenerative diseases, neurons and glia |
JP2022533702A (en) | 2019-05-20 | 2022-07-25 | パンディオン・オペレーションズ・インコーポレイテッド | MAdCAM-targeted immune tolerance |
CN114269360A (en) * | 2019-06-21 | 2022-04-01 | 恩特莱科索生物治疗公司 | Platforms, compositions and methods for therapeutic delivery |
US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
WO2021231436A1 (en) * | 2020-05-11 | 2021-11-18 | The Board Of Trustees Of The Leland Stanford Junior University | Therapeutic methods for treating covid-19 infections |
CN111575388B (en) * | 2020-06-02 | 2022-10-21 | 江汉大学 | Application of PfHMGB1 as molecular marker of algal toxin invasion and detection kit |
CN112264115B (en) * | 2020-10-26 | 2022-03-11 | 南京鼓楼医院 | Fishbone microfluidic chip carrying molecular imprinting inverse opal structure microspheres and preparation method thereof |
CN113358617B (en) * | 2021-06-02 | 2024-03-01 | 重庆大学 | Extracellular vesicle enrichment detection method |
KR20230023442A (en) | 2021-08-10 | 2023-02-17 | 현대자동차주식회사 | Vehicle body |
CN114128723B (en) * | 2021-11-09 | 2023-07-04 | 苏州大学 | Antiviral nano material and application thereof |
JP7368766B2 (en) | 2022-03-02 | 2023-10-25 | 株式会社リコー | Information processing device, information processing system, information processing method and program |
CN117887797B (en) * | 2023-12-27 | 2024-09-20 | 中国食品药品检定研究院 | Clostridium bacillus neurotoxin potency detection method |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10144252A1 (en) * | 2001-08-31 | 2003-03-27 | Fraunhofer Ges Forschung | Nanoparticles with biologically active TNF immobilized on them |
CN101123990A (en) * | 2004-10-01 | 2008-02-13 | Mida科技有限公司 | Nanoparticles comprising antigens and adjuvants and immunogenic structure |
WO2006086428A2 (en) * | 2005-02-08 | 2006-08-17 | Board Of Regents, The University Of Texas System | Particles for inactivating toxins |
EP2033660A1 (en) * | 2007-09-05 | 2009-03-11 | Freie Universität Berlin | Functionalized nanoparticles for the inhibition of selectin-mediated cell adhesion |
WO2010042555A2 (en) * | 2008-10-06 | 2010-04-15 | The Brigham And Women's Hospital, Inc. | Particles with multiple functionalized surface domains |
US20120108787A1 (en) * | 2009-02-26 | 2012-05-03 | Nubiome, Inc. | Immobilization Particles for Removal of Microorganisms and/or Chemicals |
JP6100762B2 (en) * | 2011-06-02 | 2017-03-22 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Nanoparticles encapsulated in membranes and methods of use |
CN104203092A (en) * | 2011-08-26 | 2014-12-10 | 维科纳米医药有限公司 | Pathogen and substance traps |
US20140220133A1 (en) * | 2012-11-28 | 2014-08-07 | Cytimmune Sciences, Inc. | Nanotechnology Based Medicine for Biodefense |
US20170038382A1 (en) * | 2014-01-24 | 2017-02-09 | Ntercept, Llc | Methods and compositions for immune dis-inhibition |
EA035898B1 (en) * | 2014-10-03 | 2020-08-28 | НАНОТИКС, ЭлЭлСи | Compositions and methods for inhibiting the biological activity of soluble biomolecules |
-
2016
- 2016-06-29 EA EA201890170A patent/EA201890170A1/en unknown
- 2016-06-29 CN CN202111385729.1A patent/CN114129737A/en active Pending
- 2016-06-29 MX MX2017017051A patent/MX2017017051A/en unknown
- 2016-06-29 JP JP2017568165A patent/JP7370691B2/en active Active
- 2016-06-29 WO PCT/US2016/040022 patent/WO2017004159A1/en active Application Filing
- 2016-06-29 CN CN201680049849.5A patent/CN108135848A/en active Pending
- 2016-06-29 IL IL256445A patent/IL256445B2/en unknown
- 2016-06-29 CN CN202310865497.2A patent/CN116785457A/en active Pending
- 2016-06-29 CA CA2991142A patent/CA2991142A1/en active Pending
- 2016-06-29 CN CN202310869623.1A patent/CN116763941A/en active Pending
- 2016-06-29 KR KR1020187002793A patent/KR20180043785A/en not_active Application Discontinuation
- 2016-06-29 EP EP16818651.8A patent/EP3316864A4/en active Pending
- 2016-06-29 SG SG10201913518XA patent/SG10201913518XA/en unknown
- 2016-06-29 IL IL297460A patent/IL297460A/en unknown
- 2016-06-29 US US15/738,954 patent/US20180256747A1/en active Pending
- 2016-06-29 MY MYPI2017001935A patent/MY198240A/en unknown
- 2016-06-29 AU AU2016285868A patent/AU2016285868B2/en active Active
-
2017
- 2017-12-20 MX MX2023005261A patent/MX2023005261A/en unknown
- 2017-12-20 MX MX2023005262A patent/MX2023005262A/en unknown
-
2018
- 2018-11-13 HK HK18114464.8A patent/HK1255328A1/en unknown
-
2021
- 2021-10-29 JP JP2021177516A patent/JP2022031665A/en not_active Withdrawn
-
2022
- 2022-01-14 AU AU2022200233A patent/AU2022200233B2/en active Active
-
2023
- 2023-07-13 JP JP2023114971A patent/JP2023153813A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2022200233B2 (en) | 2024-05-30 |
MX2023005262A (en) | 2023-05-23 |
JP2018524344A (en) | 2018-08-30 |
SG10201913518XA (en) | 2020-02-27 |
IL256445B (en) | 2022-11-01 |
JP7370691B2 (en) | 2023-10-30 |
MX2017017051A (en) | 2018-05-15 |
IL297460A (en) | 2022-12-01 |
IL256445B2 (en) | 2023-03-01 |
IL256445A (en) | 2018-04-30 |
WO2017004159A1 (en) | 2017-01-05 |
JP2023153813A (en) | 2023-10-18 |
EP3316864A1 (en) | 2018-05-09 |
CN116785457A (en) | 2023-09-22 |
AU2022200233A1 (en) | 2022-02-10 |
CN114129737A (en) | 2022-03-04 |
US20180256747A1 (en) | 2018-09-13 |
BR112017028315A2 (en) | 2018-09-04 |
AU2016285868B2 (en) | 2021-11-11 |
MX2023005261A (en) | 2023-05-23 |
EP3316864A4 (en) | 2019-03-06 |
CN116763941A (en) | 2023-09-19 |
JP2022031665A (en) | 2022-02-22 |
HK1255328A1 (en) | 2019-08-16 |
EA201890170A1 (en) | 2018-07-31 |
KR20180043785A (en) | 2018-04-30 |
AU2016285868A1 (en) | 2018-02-01 |
CA2991142A1 (en) | 2017-01-05 |
CN108135848A (en) | 2018-06-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023005261A (en) | Compositions and methods related to scavanger particles. | |
PH12019500709A1 (en) | Anti-lag-3 antibodies and methods of use thereof | |
EA201890391A1 (en) | MODULAR COMPOSITIONS FOR UTILIZATION OF SOLUBLE BIOMOLECULES AND RELATED METHODS | |
MX2022001222A (en) | Anti-tim-3 antibodies and methods of use thereof. | |
MX2018006973A (en) | Humanized anti-cd73 antibodies. | |
PH12019501393A1 (en) | Afucosylated anti-fgfr2iiib antibodies | |
EA201890630A1 (en) | ANTIBODIES AGAINST PD-1 AND METHODS OF THEIR APPLICATION | |
WO2018017864A3 (en) | Pvrig-binding agents and uses thereof | |
WO2016191643A3 (en) | Tigit-binding agents and uses thereof | |
BR112019011582A2 (en) | antibodies and their methods of use | |
BR112016029318A2 (en) | myeloma treatment | |
EA201791485A1 (en) | ANTI-CD47-ANTIBODIES AND THEIR APPLICATIONS | |
MX2022006304A (en) | Compositions and methods for inhibiting the biological activity of soluble biomolecules. | |
WO2016060996A3 (en) | Interleukin-15 compositions and uses thereof | |
AU2015329974A8 (en) | GaINAc phosphoramidites, nucleic acid conjugates thereof and their use | |
MX2021010668A (en) | Cytokine fusion proteins. | |
WO2017112528A3 (en) | Interleukin-15 compositions and uses thereof | |
AR108180A1 (en) | PARTICLES THAT INCLUDE SUB-PARTICLES OR STRUCTURES OF NUCLEIC ACIDS | |
EP4218790A8 (en) | Modulators of complement activity | |
WO2016160621A3 (en) | Nk-92 cells in combination therapy with cancer drugs | |
WO2017205852A3 (en) | Protein interfaces | |
WO2015010791A3 (en) | Novel antibodies for the diagnosis and treatment of rheumatoid arthritis | |
EP4306544A3 (en) | Production of heteromultimeric proteins using mammalian cells | |
WO2017040323A3 (en) | Stabilized peptides for covalent binding to target protein | |
PH12020550483A1 (en) | Anti-apoc3 antibodies and methods of use thereof |